{"id":23614,"date":"2023-06-16T15:29:22","date_gmt":"2023-06-16T09:59:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=23614"},"modified":"2023-06-16T15:29:24","modified_gmt":"2023-06-16T09:59:24","slug":"gene-therapies-for-dystrophic-epidermolysis-bullosa","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa","title":{"rendered":"Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients\u2019 Lives?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2a8e666d481\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2a8e666d481\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa\/#Entry_of_VYJUVEK_First-ever_redosable_gene_therapy\" >Entry of VYJUVEK: First-ever redosable gene therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa\/#Potential_pipeline_assets_for_dystrophic_epidermolysis_bullosa_treatment\" >Potential pipeline assets for dystrophic epidermolysis bullosa treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa\/#Clinical_challenges_remain\" >Clinical challenges remain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa\/#Will_payers_embrace_the_wave_of_costly_gene_therapies\" >Will payers embrace the wave of costly gene therapies?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB). In the United States, around <strong>3,500 <\/strong>people were <a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-epidemiology-forecast\">diagnosed with dystrophic epidermolysis bullosa<\/a> in 2021, as per DelveInsight. Out of these, approximately <strong>1,100<\/strong> people were severely affected.<\/p>\n\n\n\n<p>The current dystrophic epidermolysis bullosa treatment goal is to manage blisters and erosions, control infection, and prevent complications. Besides, symptomatic relief is also taken care of as pain and itch severely harm the patient\u2019s quality of life. Moreover, surgical dystrophic epidermolysis bullosa treatments provide a symptomatic improvement from many deformities and skin tumors.\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"376\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151720\/Dystrophic-Epidermolysis-Bullosa-Epidemiology-Insights-1024x376.png\" alt=\"Dystrophic Epidermolysis Bullosa Epidemiology Insights\" class=\"wp-image-23623\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151720\/Dystrophic-Epidermolysis-Bullosa-Epidemiology-Insights-1024x376.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151720\/Dystrophic-Epidermolysis-Bullosa-Epidemiology-Insights-300x110.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151720\/Dystrophic-Epidermolysis-Bullosa-Epidemiology-Insights-150x55.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151720\/Dystrophic-Epidermolysis-Bullosa-Epidemiology-Insights-768x282.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151720\/Dystrophic-Epidermolysis-Bullosa-Epidemiology-Insights.png 1213w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><strong>Dystrophic Epidermolysis Bullosa Epidemiology Trends<\/strong><\/figcaption><\/figure>\n\n\n\n<p>According to DelveInsight\u2019s estimates, the current symptomatic <a href=\"https:\/\/www.delveinsight.com\/blog\/dystrophic-epidermolysis-bullosa-treatment-market\">market of dystrophic epidermolysis bullosa<\/a> is around <strong>USD 350 million<\/strong> in the United States. Advancements in genetic testing and disease understanding are likely to fuel the dystrophic epidermolysis bullosa treatment market growth. The respective portfolios of several biopharma companies feature multiple pipeline projects focused on the development of newer treatment options like cell-based therapies, gene therapies, protein replacement therapies, and autologous and allogeneic stem cell therapies, among others. Gene therapies, which involve the transfer of functional COL7A1 gene to the patient with RDEB, appear to be at the forefront as promising potential treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Entry_of_VYJUVEK_First-ever_redosable_gene_therapy\"><\/span><strong>Entry of VYJUVEK: First-ever redosable gene therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Recently, on 19 May 2023, <strong>Krystal Biotech, Inc.,<\/strong> a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced that the FDA has approved <strong>VYJUVEK (beremagene geperpavec-svdt)<\/strong> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-market\">treatment of dystrophic epidermolysis bullosa patients<\/a> 6 months of age or older. VYJUVEK is intended to treat the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene, resulting in wound healing and sustained functional COL7 protein expression with redosing. VYJUVEK is the first and only FDA-approved drug for dystrophic epidermolysis bullosa treatment, both recessive and dominant, that can be administered by a healthcare professional in either a healthcare professional setting or at home.<\/p>\n\n\n\n<p>VYJUVEK was approved by the FDA based on two clinical investigations. The <strong>GEM-1\/II trial <\/strong>was an intra-patient, open-label, single-center, randomized, placebo-controlled study that found that repeat topical applications of VYJUVEK were associated with long-term wound closure, full-length cutaneous COL7 expression, and anchoring fibril assembly with few adverse events. The GEM-3 experiment was an intra-patient, double-blind, multicenter, randomized, placebo-controlled study that fulfilled both its primary and secondary endpoints of full wound healing at six months and three months. VYJUVEK was well tolerated, with no drug-related major adverse events or treatment-related discontinuations.<\/p>\n\n\n\n<p>VYJUVEK will be accessible in the United States in the third quarter of 2023, and the Company will begin marketing it immediately. Krystal Connect, a personalized support program, was designed by the Company to fulfill the needs of patients, carers, and families as they begin and continue their VYJUVEK treatment journey. The program comprises services that may answer VYJUVEK-related queries, verify health benefits, aid with treatment planning and administration, and provide information about financial assistance for qualified patients. Patients, carers, and healthcare professionals can get further information by calling 1-844-5-KRYSTAL.<\/p>\n\n\n\n<p>The FDA granted the company a Rare Paediatric Disease Priority Review Voucher (PRV), which grants priority review to a subsequent medication application that would not otherwise qualify for priority review. The PRV program promotes the discovery of novel medications for the prevention or <a href=\"https:\/\/www.delveinsight.com\/blog\/rare-diseases\">treatment of rare diseases<\/a>.<\/p>\n\n\n\n<p>Outside of the United States, the European Medicines Agency has designated VYJUVEK as an orphan drug and granted it PRIME (PRIority MEdicines) status for the treatment of dystrophic epidermolysis bullosa. The Company expects to begin the official Marketing Authorization Application procedure in the second half of 2023, with approval possible in 2024. The company is also collaborating with Japan\u2019s Pharmaceuticals and Medical Devices Agency to examine VYJUVEK and seek permission for a possible launch in 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Potential_pipeline_assets_for_dystrophic_epidermolysis_bullosa_treatment\"><\/span><strong>Potential pipeline assets for dystrophic epidermolysis bullosa treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Many companies are developing possible treatments for dystrophic epidermolysis bullosa with continuous efforts in research and development. <strong>Castle Creek Biosciences (FCX-007), Amryt Pharma (Oleogel-S10), Abeona Therapeutics (EB-101), and Phoenix Tissue Repair (PTR-01)<\/strong> are key players working on <a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight\">potential dystrophic epidermolysis bullosa therapies<\/a> like gene therapy, symptomatic relief therapy, and disease-modifying therapies.\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight\"><img decoding=\"async\" width=\"1024\" height=\"371\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151829\/Dystrophic-Epidermolysis-Bullosa-Pipeline-Therapies-1024x371.png\" alt=\"Dystrophic Epidermolysis Bullosa Pipeline Therapies\" class=\"wp-image-23626\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151829\/Dystrophic-Epidermolysis-Bullosa-Pipeline-Therapies-1024x371.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151829\/Dystrophic-Epidermolysis-Bullosa-Pipeline-Therapies-300x109.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151829\/Dystrophic-Epidermolysis-Bullosa-Pipeline-Therapies-150x54.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151829\/Dystrophic-Epidermolysis-Bullosa-Pipeline-Therapies-768x278.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151829\/Dystrophic-Epidermolysis-Bullosa-Pipeline-Therapies.png 1212w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><figcaption class=\"wp-element-caption\"><strong>Dystrophic Epidermolysis Bullosa Pipeline Therapies<\/strong><\/figcaption><\/figure>\n\n\n\n<p><strong>FCX-007 (Dabocemagene autoficel)<\/strong> is an investigational gene therapy to address functional type VII collagen protein (COL7) deficiency in patients with DEB. It is a genetically-modified autologous fibroblast that encodes the gene for COL7 and treats wounds locally via injection. Further, <strong>EB-101<\/strong> an autologous, gene-corrected cell therapy for RDEB involves using gene transfer technology to deliver COL7A1 genes into an RDEB patient\u2019s skin cells (keratinocytes) and transplanting them back to the patient to enable normal type VII collagen expression.<\/p>\n\n\n\n<p>Apart from the promising gene therapies, other therapies are also in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-pipeline-insight\">dystrophic epidermolysis bullosa pipeline<\/a>. <strong>PTR-01<\/strong> is an intravenous protein replacement therapy that uses a recombinant collagen type VII (Rc7) to treat RDEB. Apart from this, <strong>RGN-137 (Lenus Therapeutics) and INM-755 (InMed Pharmaceutical)<\/strong> are the two topical therapies recruiting subjects in the Phase II trial of clinical development for treating Epidermolysis Bullosa.&nbsp;<\/p>\n\n\n\n<p>By successfully testing and launching these emerging therapies, the <a href=\"https:\/\/www.delveinsight.com\/blog\/dystrophic-epidermolysis-bullosa-treatment-market\">total dystrophic epidermolysis bullosa treatment market<\/a> will increase and is poised to reach approximately <strong>USD 1 billion<\/strong> in the seven major markets by 2032.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/dystrophic-epidermolysis-bullosa-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-1024x194.png\" alt=\"Dystrophic Epidermolysis Bullosa Market Outlook Infographics\" class=\"wp-image-23629\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151925\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-Infographics.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Clinical_challenges_remain\"><\/span><strong>Clinical challenges remain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With the advent of curative therapies, the upcoming dystrophic epidermolysis bullosa therapeutic landscape looks promising. However, a few challenges need to be looked at; ex-vivo autologous gene replacement therapy involves isolating patient cells, genetically correcting them in vitro by introducing wild-type cDNA copies of the affected gene, expanding the corrected cells into epidermal sheets, and grafting these back onto chronic wounds. This form of therapy is mainly investigated in severe EB types (JEB, RDEB), which typically display an autosomal recessive inheritance.&nbsp;<\/p>\n\n\n\n<p>Moreover, the current gene delivery techniques cannot specifically target epidermal stem cells called holoclones in vivo. Further, ensuring efficient targeting of these epidermal stem cells first requires their isolation before introducing the replacement gene ex-vivo. However, proper signaling is restored upon reintroducing the wild-type LAMB3 cDNA, thereby imparting a replicative advantage to corrected clones in JEB.<\/p>\n\n\n\n<p>However, this is not the case with RDEB, which poses several challenges, like the significantly greater size of the COL7A1 transcript, the YAP\/TAZ pathway being unaffected, and transduced clones not gaining a replicative advantage. Consequently, this approach is far less prominent in RDEB. Besides, gene-targeted therapies face common issues of efficacy, safety, feasibility, tolerability, and cost-effectiveness.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-will-payers-embrace-the-wave-of-costly-gene-therapies\"><span class=\"ez-toc-section\" id=\"Will_payers_embrace_the_wave_of_costly_gene_therapies\"><\/span><strong>Will payers embrace the wave of costly gene therapies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Reimbursement of durable and potentially curative <a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-market\">dystrophic epidermolysis bullosa gene therapies<\/a> will challenge payers in US and EU regions due to their high upfront costs. The lack of long-term clinical studies magnifies uncertainties which will be challenging for payer coverage and reimbursement decisions. These characteristics could negatively impact patient access and, ultimately, future developer innovation.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-1024x256.png\" alt=\"Dystrophic Epidermolysis Bullosa Market Outlook\" class=\"wp-image-23619\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151535\/Dystrophic-Epidermolysis-Bullosa-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>FAQs<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1686907716183\"><strong class=\"schema-faq-question\">What is dystrophic epidermolysis bullosa?<\/strong> <p class=\"schema-faq-answer\">Dystrophic epidermolysis bullosa is one of the most common types of epidermolysis bullosa. Epidermolysis bullosa causes the skin to be extremely delicate and to blister readily.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1686907723414\"><strong class=\"schema-faq-question\">What are the symptoms of dystrophic epidermolysis bullosa?<\/strong> <p class=\"schema-faq-answer\">The common signs and dystrophic epidermolysis bullosa symptoms include blisters, itchy, painful skin, dysphagia, dental problems, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1686907730806\"><strong class=\"schema-faq-question\">What are the dystrophic epidermolysis bullosa causes?<\/strong> <p class=\"schema-faq-answer\">The dystrophic epidermolysis bullosa causes are generally inherited. The disease&#8217;s gene may be passed down from one of the disease&#8217;s parents (autosomal dominant inheritance)<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1686907739190\"><strong class=\"schema-faq-question\">What are the current dystrophic epidermolysis bullosa treatment options?<\/strong> <p class=\"schema-faq-answer\">The current dystrophic epidermolysis bullosa treatment includes contemporary wound care and the reduction of external factors that cause blistering and hinder wound healing. A high degree of personal hygiene and intense moisturizing dystrophic epidermolysis bullosa treatment is required for proper skin care.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into recessive dystrophic epidermolysis bullosa (RDEB) and [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":23616,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19615,19616,19618,19617,257,502],"industry":[17225],"therapeutic_areas":[17237,17238,17227,17243],"class_list":["post-23614","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dystrophic-epidermolysis-bullosa","tag-dystrophic-epidermolysis-bullosa-market","tag-dystrophic-epidermolysis-bullosa-pipeline","tag-dystrophic-epidermolysis-bullosa-treatment","tag-gene-therapies","tag-rare-disease","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Potential of Gene Therapies for Dystrophic Epidermolysis Bullosa<\/title>\n<meta name=\"description\" content=\"Gene Therapies are set to play a key role in the Dystrophic Epidermolysis Bullosa (DEB) treatment market. Companies are developing therapies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Potential of Gene Therapies for Dystrophic Epidermolysis Bullosa\" \/>\n<meta property=\"og:description\" content=\"Gene Therapies are set to play a key role in the Dystrophic Epidermolysis Bullosa (DEB) treatment market. Companies are developing therapies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-16T09:59:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-16T09:59:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151304\/Gene-Therapies-for-Dystrophic-Epidermolysis-Bullosa.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Potential of Gene Therapies for Dystrophic Epidermolysis Bullosa","description":"Gene Therapies are set to play a key role in the Dystrophic Epidermolysis Bullosa (DEB) treatment market. Companies are developing therapies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa","og_locale":"en_US","og_type":"article","og_title":"Potential of Gene Therapies for Dystrophic Epidermolysis Bullosa","og_description":"Gene Therapies are set to play a key role in the Dystrophic Epidermolysis Bullosa (DEB) treatment market. Companies are developing therapies","og_url":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-06-16T09:59:22+00:00","article_modified_time":"2023-06-16T09:59:24+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151304\/Gene-Therapies-for-Dystrophic-Epidermolysis-Bullosa.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa","url":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa","name":"Potential of Gene Therapies for Dystrophic Epidermolysis Bullosa","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151304\/Gene-Therapies-for-Dystrophic-Epidermolysis-Bullosa.png","datePublished":"2023-06-16T09:59:22+00:00","dateModified":"2023-06-16T09:59:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Gene Therapies are set to play a key role in the Dystrophic Epidermolysis Bullosa (DEB) treatment market. Companies are developing therapies","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907716183"},{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907723414"},{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907730806"},{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907739190"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151304\/Gene-Therapies-for-Dystrophic-Epidermolysis-Bullosa.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151304\/Gene-Therapies-for-Dystrophic-Epidermolysis-Bullosa.png","width":1200,"height":800,"caption":"Gene Therapies for Dystrophic Epidermolysis Bullosa"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907716183","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907716183","name":"What is dystrophic epidermolysis bullosa?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Dystrophic epidermolysis bullosa is one of the most common types of epidermolysis bullosa. Epidermolysis bullosa causes the skin to be extremely delicate and to blister readily.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907723414","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907723414","name":"What are the symptoms of dystrophic epidermolysis bullosa?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The common signs and dystrophic epidermolysis bullosa symptoms include blisters, itchy, painful skin, dysphagia, dental problems, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907730806","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907730806","name":"What are the dystrophic epidermolysis bullosa causes?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The dystrophic epidermolysis bullosa causes are generally inherited. The disease's gene may be passed down from one of the disease's parents (autosomal dominant inheritance)","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907739190","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/gene-therapies-for-dystrophic-epidermolysis-bullosa#faq-question-1686907739190","name":"What are the current dystrophic epidermolysis bullosa treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The current dystrophic epidermolysis bullosa treatment includes contemporary wound care and the reduction of external factors that cause blistering and hinder wound healing. A high degree of personal hygiene and intense moisturizing dystrophic epidermolysis bullosa treatment is required for proper skin care.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/06\/16151304\/Gene-Therapies-for-Dystrophic-Epidermolysis-Bullosa-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa<\/span>","<span class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa market<\/span>","<span class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa pipeline<\/span>","<span class=\"advgb-post-tax-term\">dystrophic epidermolysis bullosa treatment<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 16, 2023","modified":"Updated on Jun 16, 2023"},"absolute_dates_time":{"created":"Posted on Jun 16, 2023 3:29 pm","modified":"Updated on Jun 16, 2023 3:29 pm"},"featured_img_caption":"Gene Therapies for Dystrophic Epidermolysis Bullosa","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=23614"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/23614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/23616"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=23614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=23614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=23614"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=23614"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=23614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}